Candel Therapeutics, Inc.
Clinical trials sponsored by Candel Therapeutics, Inc., explained in plain language.
Clinical-stage biopharmaceutical company developing viral immunotherapies for cancer.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New gene therapy injection aims to boost prostate cancer radiation results Results expected Feb 2027 (estimated)
-
New gene therapy injection aims to boost prostate cancer radiation results
Disease control Recruiting nowThis study tests a gene therapy called aglatimagene besadenovec, given with valacyclovir, in 45 men with intermediate-risk prostate cancer who will also receive radiation. The main goal is to see how the therapy spreads in the body and to measure immune responses and tumor marker…
Phase 2 • Sponsor: Candel Therapeutics, Inc. • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Engineered virus plus immunotherapy aims to outperform chemo in advanced lung cancer
Disease control Recruiting nowThis phase 3 trial tests whether a combination of an injected virus therapy (CAN-2409) and an immunotherapy drug (pembrolizumab) can help people with stage IV non-squamous non-small cell lung cancer live longer than standard chemotherapy. The virus is designed to kill tumor cells…
Phase 3 • Sponsor: Candel Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC